Jump Financial’s enGene Therapeutics ENGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$147K Buy
21,633
+8,233
+61% +$73.3K ﹤0.01% 1718
2025
Q4
$121K Buy
+13,400
New +$107K ﹤0.01% 1815

Other funds holding ENGN

Jump Financial's ENGN Position: Q1 2026 in Review

Jump Financial increased its enGene Therapeutics (ENGN) stake by 61% in Q1 2026, buying an estimated $73.3K and bringing the position to 21,633 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1718.

Jump Financial first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Jump Financial held 21,633 shares of enGene Therapeutics worth $147K as of Q1 2026.
  • Jump Financial bought 8,233 enGene Therapeutics shares in Q1 2026, an estimated $73.3K.
  • enGene Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1718 holding.
  • Jump Financial first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.